RAS inhibitor/CCB combination therapy

The combination of RAS inhibitors with DHP-CCBs may provide more intensive BP control to currently recommended targets and cardiovascular protective effects that lead to more global risk-factor reduction in patients with hypertension. Given their excellent and complementary tolerability profiles, combination therapy with an ARB or ACEI with a long-acting DHP-CCB is a rational choice for patients requiring two or more antihypertensive agents.Read the review article here..